Cigna Profits Hit Nearly $2 Billion Despite Rising Costs

The Cigna Group reported robust third-quarter results, with net income reaching $1.9 billion ($6.98 per share), a significant increase from $0.7 billion in the prior year, and total revenues climbing 10% to $69.7 billion, largely propelled by its Evernorth Health Services segment. While the company's medical cost ratio rose to 84.8% due to individual and family plans and higher stop-loss costs, this figure remains below many industry rivals, partly attributable to Cigna's earlier divestiture of its Medicare businesses. This performance underscores Cigna's strategic execution and business breadth amidst a dynamic healthcare cost environment.

Analysis

The Cigna Group reported robust third-quarter 2025 results, with net income reaching $1.9 billion, or $6.98 per share, a significant increase from the $0.7 billion ($2.63 per share) reported in Q3 2024, which included a $1.0 billion one-time investment loss. Total revenues climbed 10% year-over-year to $69.7 billion, primarily driven by strong performance in its Evernorth Health Services segment, including growth in existing client relationships and specialty pharmacy.

Despite rising medical expenses, Cigna's medical cost ratio (MCR) increased to 84.8% in Q3 2025 from 82.8% in Q3 2024, attributed to individual and family plans and higher stop-loss costs. However, this MCR remains notably below many industry rivals, which are experiencing ratios of 90% or more. This relative outperformance is partly due to Cigna's strategic divestiture of its Medicare businesses earlier this year, differentiating its cost profile from peers heavily exposed to government-subsidized plans.

CEO David M. Cordani emphasized that these strong quarterly results reflect the company's broad business portfolio and focused execution on its growth strategy amidst a dynamic environment. The positive sentiment surrounding these results, with a sentiment score of 0.75, suggests a favorable market reaction to Cigna's operational resilience and strategic positioning.

Key Decisions for Investors

• Investors should assess Cigna's strong operational execution, highlighted by robust Q3 earnings and revenue growth, particularly from Evernorth Health Services, which positions it favorably against industry cost pressures.
• Monitor the trajectory of Cigna's medical cost ratio (MCR) and the continued expansion of its specialty pharmacy and PBM businesses within Evernorth, as these are key drivers of future profitability.
• Consider Cigna's strategic differentiation from peers due to its Medicare business divestiture, which may offer a more insulated risk profile from government-subsidized plan challenges.